REVIEW LEDGER
论文复核台
集中查看元数据入排不确定项,以及已识别 KM 但需确认 No. at risk 的内容复核项。
| 论文 | 元数据入排 | 图像/No. at risk 复核 | 依据 |
|---|---|---|---|
| Surufatinib in advanced neuroendocrine tumours: Final overall survival from two randomised, double-blind, placebo-controlled phase 3 studies (SANET-ep and SANET-p).PMID 40306120 · 2025-Jun-03 | eligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | needs_review历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。 | 历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。 |
| Patient-reported outcomes in the subpopulation of patients with mismatch repair-deficient/microsatellite instability-high primary advanced or recurrent endometrial cancer treated with dostarlimab plus chemotherapy compared with chemotherapy alone in the ENGOT-EN6-NSGO/GOG3031/RUBY trial.PMID 39322611 · 2025-Jun | eligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | needs_review未获得 PubMed/PMC 可审查 Figure,无法核实 KM 曲线与 No. at risk 表。 | 未获得 PubMed/PMC 可审查 Figure,无法核实 KM 曲线与 No. at risk 表。 |
| Exploring Early Kinetic Profiles of CEA, ctDNA and cfDNA in Patients With RAS-/BRAF-Mutated Metastatic Colorectal Cancer.PMID 39743478 · 2025-Jun | eligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | needs_review未获得 PubMed/PMC 可审查 Figure,无法核实 KM 曲线与 No. at risk 表。 | 未获得 PubMed/PMC 可审查 Figure,无法核实 KM 曲线与 No. at risk 表。 |
| Impact of Treatment With Trifluridine/Tipiracil in Combination With Bevacizumab on Health-Related Quality of Life and Performance Status in Refractory Metastatic Colorectal Cancer: An Analysis of the Phase III SUNLIGHT Trial.PMID 39818468 · 2025-Jun | eligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | needs_review未获得 PubMed/PMC 可审查 Figure,无法核实 KM 曲线与 No. at risk 表。 | 未获得 PubMed/PMC 可审查 Figure,无法核实 KM 曲线与 No. at risk 表。 |
| Final Overall Survival and Molecular Data Associated with Clinical Outcomes in Patients Receiving Ipatasertib and Abiraterone in the Phase 3 IPATential150 Trial.PMID 39884884 · 2025-Jun | eligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | needs_review未获得 PubMed/PMC 可审查 Figure,无法核实 KM 曲线与 No. at risk 表。 | 未获得 PubMed/PMC 可审查 Figure,无法核实 KM 曲线与 No. at risk 表。 |
| Early toxicity of moderately hypofractionated radiation therapy in breast cancer patients receiving locoregional irradiation: First results of the UNICANCER HypoG-01 phase III trial.PMID 40097073 · 2025-Jun | eligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | needs_review未获得 PubMed/PMC 可审查 Figure,无法核实 KM 曲线与 No. at risk 表。 | 未获得 PubMed/PMC 可审查 Figure,无法核实 KM 曲线与 No. at risk 表。 |
| Olaparib Plus Abiraterone in Asian Patients With Metastatic Castration-Resistant Prostate Cancer: PROpel Subset Analysis.PMID 40099663 · 2025-Jun | eligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | needs_review历史记录已识别 KM 曲线,但旧版 Figure 审查未记录 No. at risk 表;需复核正文或补充材料。 | 历史记录已识别 KM 曲线,但旧版 Figure 审查未记录 No. at risk 表;需复核正文或补充材料。 |
| Impact of adding palbociclib on treatment adherence to ongoing adjuvant endocrine treatment in the global randomized PALLAS randomized trial in patients with early breast cancer.PMID 40140172 · 2025-Jun | eligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | needs_review未获得 PubMed/PMC 可审查 Figure,无法核实 KM 曲线与 No. at risk 表。 | 未获得 PubMed/PMC 可审查 Figure,无法核实 KM 曲线与 No. at risk 表。 |
| Estimating the Impact of Adjuvant Treatment With Nivolumab on Long-Term Survivorship Rates Compared With Surveillance in Muscle Invasive Urothelial Carcinoma: Mixture Cure Modeling Analyses of Disease-Free Survival From the Phase 3 CheckMate 274 Trial.PMID 40204616 · 2025-Jun | eligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | needs_review未获得 PubMed/PMC 可审查 Figure,无法核实 KM 曲线与 No. at risk 表。 | 未获得 PubMed/PMC 可审查 Figure,无法核实 KM 曲线与 No. at risk 表。 |
| Sacituzumab tirumotecan in previously treated metastatic triple-negative breast cancer: a randomized phase 3 trial.PMID 40217078 · 2025-Jun | eligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | needs_review未获得 PubMed/PMC 可审查 Figure,无法核实 KM 曲线与 No. at risk 表。 | 未获得 PubMed/PMC 可审查 Figure,无法核实 KM 曲线与 No. at risk 表。 |
| TFOX versus FOLFOX in first-line treatment of patients with advanced HER2-negative gastric or gastro-oesophageal junction adenocarcinoma (PRODIGE 51- FFCD-GASTFOX): an open-label, multicentre, randomised, phase 3 trial.PMID 40286809 · 2025-Jun | eligible命中用户提供的消化道肿瘤阳性参考集。 | needs_review未获得 PubMed/PMC 可审查 Figure,无法核实 KM 曲线与 No. at risk 表。 | 未获得 PubMed/PMC 可审查 Figure,无法核实 KM 曲线与 No. at risk 表。 |
| Amivantamab plus lazertinib versus osimertinib as first-line treatment in EGFR-mutated advanced non-small cell lung cancer: MARIPOSA Asian subset.PMID 40300278 · 2025-Jun | eligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | needs_review未获得 PubMed/PMC 可审查 Figure,无法核实 KM 曲线与 No. at risk 表。 | 未获得 PubMed/PMC 可审查 Figure,无法核实 KM 曲线与 No. at risk 表。 |
| Anlotinib plus penpulimab versus sorafenib in the first-line treatment of unresectable hepatocellular carcinoma (APOLLO): a randomised, controlled, phase 3 trial.PMID 40349716 · 2025-Jun | eligible命中用户提供的消化道肿瘤阳性参考集。 | needs_review未获得 PubMed/PMC 可审查 Figure,无法核实 KM 曲线与 No. at risk 表。 | 未获得 PubMed/PMC 可审查 Figure,无法核实 KM 曲线与 No. at risk 表。 |
| Enfortumab vedotin plus pembrolizumab versus chemotherapy in patients with previously untreated locally advanced or metastatic urothelial cancer (EV-302): patient-reported outcomes from an open-label, randomised, controlled, phase 3 study.PMID 40449498 · 2025-Jun | eligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | needs_review未获得 PubMed/PMC 可审查 Figure,无法核实 KM 曲线与 No. at risk 表。 | 未获得 PubMed/PMC 可审查 Figure,无法核实 KM 曲线与 No. at risk 表。 |
| Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first-line treatment of advanced gastric or gastroesophageal junction adenocarcinoma: patient-reported outcomes in the RATIONALE-305 study.PMID 40528576 · 2025-Jun | eligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | needs_review未获得 PubMed/PMC 可审查 Figure,无法核实 KM 曲线与 No. at risk 表。 | 未获得 PubMed/PMC 可审查 Figure,无法核实 KM 曲线与 No. at risk 表。 |
| Transarterial chemoembolization plus apatinib for unresectable hepatocellular carcinoma: a multicenter, randomized, open-label, phase III trial.PMID 40437469 · 2025-May-28 | eligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | needs_review历史记录已识别 KM 曲线,但旧版 Figure 审查未记录 No. at risk 表;需复核正文或补充材料。 | 历史记录已识别 KM 曲线,但旧版 Figure 审查未记录 No. at risk 表;需复核正文或补充材料。 |
| Nivolumab plus ipilimumab versus lenvatinib or sorafenib as first-line treatment for unresectable hepatocellular carcinoma (CheckMate 9DW): an open-label, randomised, phase 3 trial.PMID 40349714 · 2025-May-24 | eligible命中用户提供的消化道肿瘤阳性参考集。 | needs_review未获得 PubMed/PMC 可审查 Figure,无法核实 KM 曲线与 No. at risk 表。 | 未获得 PubMed/PMC 可审查 Figure,无法核实 KM 曲线与 No. at risk 表。 |
| Randomized, Open-Label, Phase III Study of Tilsotolimod in Combination With Ipilimumab Versus Ipilimumab Alone in Patients With Advanced Refractory Melanoma (ILLUMINATE-301).PMID 40048691 · 2025-May-20 | eligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | needs_review未获得 PubMed/PMC 可审查 Figure,无法核实 KM 曲线与 No. at risk 表。 | 未获得 PubMed/PMC 可审查 Figure,无法核实 KM 曲线与 No. at risk 表。 |
| High-Dose Methotrexate in Children and Young Adults With ALL and Lymphoblastic Lymphoma: Results of the Randomized Phase III Study UKALL 2011.PMID 40193822 · 2025-May-20 | eligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | needs_review历史记录已识别 KM 曲线,但旧版 Figure 审查未记录 No. at risk 表;需复核正文或补充材料。 | 历史记录已识别 KM 曲线,但旧版 Figure 审查未记录 No. at risk 表;需复核正文或补充材料。 |
| Pembrolizumab with or without chemotherapy in recurrent or metastatic head and neck squamous cell carcinoma: 5-year follow-up from the randomized phase III KEYNOTE-048 study.PMID 40262400 · 2025-May-15 | eligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | needs_review未获得 PubMed/PMC 可审查 Figure,无法核实 KM 曲线与 No. at risk 表。 | 未获得 PubMed/PMC 可审查 Figure,无法核实 KM 曲线与 No. at risk 表。 |
| Adjuvant PD-1 Blockade With Camrelizumab for Nasopharyngeal Carcinoma: The DIPPER Randomized Clinical Trial.PMID 40079940 · 2025-May-13 | eligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | needs_review历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。 | 历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。 |
| Atezolizumab in High-Risk Locally Advanced Squamous Cell Carcinoma of the Head and Neck: A Randomized Clinical Trial.PMID 40079944 · 2025-May-13 | eligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | needs_review历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。 | 历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。 |
| Neoadjuvant PARP inhibitor scheduling in BRCA1 and BRCA2 related breast cancer: PARTNER, a randomized phase II/III trial.PMID 40360463 · 2025-May-13 | eligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | needs_review历史记录已识别 KM 曲线,但旧版 Figure 审查未记录 No. at risk 表;需复核正文或补充材料。 | 历史记录已识别 KM 曲线,但旧版 Figure 审查未记录 No. at risk 表;需复核正文或补充材料。 |
| Upadacitinib as monotherapy in patients with rheumatoid arthritis and prior inadequate response to methotrexate: results at 260 weeks from the SELECT-MONOTHERAPY randomised study.PMID 40350200 · 2025-May-11 | needs_reviewThe record is a randomized, phase III trial of a drug (upadacitinib) in a human, but it is for rheumatoid arthritis, not a malignant neoplasm. Therefore, it fails the core oncology criterion. | pending- | The record is a randomized, phase III trial of a drug (upadacitinib) in a human, but it is for rheumatoid arthritis, not a malignant neoplasm. Therefore, it fails the core oncology criterion. |
| Pertuzumab Retreatment for Human Epidermal Growth Factor Receptor 2-Positive Locally Advanced/Metastatic Breast Cancer (PRECIOUS Study): Final Overall Survival Analysis.PMID 39854662 · 2025-May-10 | eligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | needs_review历史记录已识别 KM 曲线,但旧版 Figure 审查未记录 No. at risk 表;需复核正文或补充材料。 | 历史记录已识别 KM 曲线,但旧版 Figure 审查未记录 No. at risk 表;需复核正文或补充材料。 |
| Pembrolizumab Plus Docetaxel Versus Docetaxel for Previously Treated Metastatic Castration-Resistant Prostate Cancer: The Randomized, Double-Blind, Phase III KEYNOTE-921 Trial.PMID 40043230 · 2025-May-10 | eligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | needs_review历史记录已识别 KM 曲线,但旧版 Figure 审查未记录 No. at risk 表;需复核正文或补充材料。 | 历史记录已识别 KM 曲线,但旧版 Figure 审查未记录 No. at risk 表;需复核正文或补充材料。 |
| Capivasertib plus fulvestrant in patients with HR-positive/HER2-negative advanced breast cancer: phase 3 CAPItello-291 study extended Chinese cohort.PMID 40346047 · 2025-May-09 | eligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | needs_review历史记录已识别 KM 曲线,但旧版 Figure 审查未记录 No. at risk 表;需复核正文或补充材料。 | 历史记录已识别 KM 曲线,但旧版 Figure 审查未记录 No. at risk 表;需复核正文或补充材料。 |
| Daratumumab or Active Monitoring for High-Risk Smoldering Multiple Myeloma.PMID 39652675 · 2025-May-08 | eligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | needs_review未获得 PubMed/PMC 可审查 Figure,无法核实 KM 曲线与 No. at risk 表。 | 未获得 PubMed/PMC 可审查 Figure,无法核实 KM 曲线与 No. at risk 表。 |
| First-line treatment of anti-EGFR monoclonal antibody cetuximab β plus FOLFIRI versus FOLFIRI alone in Chinese patients with RAS/BRAF wild-type metastatic colorectal cancer: a randomized, phase 3 trial.PMID 40328753 · 2025-May-07 | eligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | needs_review历史记录已识别 KM 曲线,但旧版 Figure 审查未记录 No. at risk 表;需复核正文或补充材料。 | 历史记录已识别 KM 曲线,但旧版 Figure 审查未记录 No. at risk 表;需复核正文或补充材料。 |
| Radiation vs. trans-oral surgery for treatment de-escalation in HPV-related oropharyngeal cancers: Primary analysis of the ORATOR2 randomized trial.PMID 40121836 · 2025-May-02 | eligible明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。 | needs_review未获得 PubMed/PMC 可审查 Figure,无法核实 KM 曲线与 No. at risk 表。 | 未获得 PubMed/PMC 可审查 Figure,无法核实 KM 曲线与 No. at risk 表。 |
| Patient-reported outcomes with adjuvant nivolumab versus placebo after complete resection of stage IIB/C melanoma in the randomized phase 3 CheckMate 76 K trial.PMID 40139004 · 2025-May-02 | eligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | needs_review未获得 PubMed/PMC 可审查 Figure,无法核实 KM 曲线与 No. at risk 表。 | 未获得 PubMed/PMC 可审查 Figure,无法核实 KM 曲线与 No. at risk 表。 |
| Race and clinical outcomes in hormone receptor-positive, HER2-negative, node-positive breast cancer in the randomized RxPONDER trial.PMID 39656951 · 2025-May-01 | eligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | needs_review未获得 PubMed/PMC 可审查 Figure,无法核实 KM 曲线与 No. at risk 表。 | 未获得 PubMed/PMC 可审查 Figure,无法核实 KM 曲线与 No. at risk 表。 |
| Fulvestrant Versus Anastrozole in Endocrine Therapy-Naïve Women With Hormone Receptor-Positive Advanced Breast Cancer: Final Overall Survival in the Phase III FALCON Trial.PMID 39772884 · 2025-May | eligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | needs_review历史记录已识别 KM 曲线,但旧版 Figure 审查未记录 No. at risk 表;需复核正文或补充材料。 | 历史记录已识别 KM 曲线,但旧版 Figure 审查未记录 No. at risk 表;需复核正文或补充材料。 |
| Pomalidomide, Bortezomib, and Dexamethasone Versus Bortezomib and Dexamethasone in Relapsed or Refractory Multiple Myeloma: Final Survival and Subgroup Analyses From the OPTIMISMM Trial.PMID 39777934 · 2025-May | eligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | needs_review未获得 PubMed/PMC 可审查 Figure,无法核实 KM 曲线与 No. at risk 表。 | 未获得 PubMed/PMC 可审查 Figure,无法核实 KM 曲线与 No. at risk 表。 |
| A randomised phase III study of bevacizumab and carboplatin-pemetrexed chemotherapy with or without atezolizumab as first-line treatment for advanced pleural mesothelioma: results of the ETOP 13-18 BEAT-meso trial.PMID 39814199 · 2025-May | eligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | needs_review未获得 PubMed/PMC 可审查 Figure,无法核实 KM 曲线与 No. at risk 表。 | 未获得 PubMed/PMC 可审查 Figure,无法核实 KM 曲线与 No. at risk 表。 |
| Digital Profiling of Immune Biomarkers in Breast Cancer: Relation to Anthracycline Benefit.PMID 39863112 · 2025-May | eligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | needs_review未获得 PubMed/PMC 可审查 Figure,无法核实 KM 曲线与 No. at risk 表。 | 未获得 PubMed/PMC 可审查 Figure,无法核实 KM 曲线与 No. at risk 表。 |
| First-Line Mobocertinib Versus Platinum-Based Chemotherapy in Patients With EGFR Exon 20 Insertion-Positive Metastatic Non-Small Cell Lung Cancer in the Phase III EXCLAIM-2 Trial.PMID 39879577 · 2025-May | eligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | needs_review历史记录已识别 KM 曲线,但旧版 Figure 审查未记录 No. at risk 表;需复核正文或补充材料。 | 历史记录已识别 KM 曲线,但旧版 Figure 审查未记录 No. at risk 表;需复核正文或补充材料。 |
| Using methods to extend inferences to specific target populations to improve the precision of subgroup analyses.PMID 39924128 · 2025-May | eligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | needs_review历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。 | 历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。 |
| Sacituzumab govitecan in advanced urothelial carcinoma: TROPiCS-04, a phase III randomized trial.PMID 39934055 · 2025-May | eligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | needs_review未获得 PubMed/PMC 可审查 Figure,无法核实 KM 曲线与 No. at risk 表。 | 未获得 PubMed/PMC 可审查 Figure,无法核实 KM 曲线与 No. at risk 表。 |
| Pembrolizumab plus chemotherapy in advanced or recurrent endometrial cancer: overall survival and exploratory analyses of the NRG GY018 phase 3 randomized trial.PMID 40044930 · 2025-May | eligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | needs_review历史记录已识别 KM 曲线,但旧版 Figure 审查未记录 No. at risk 表;需复核正文或补充材料。 | 历史记录已识别 KM 曲线,但旧版 Figure 审查未记录 No. at risk 表;需复核正文或补充材料。 |
| Bortezomib, melphalan, and prednisone with or without daratumumab in transplant-ineligible patients with newly diagnosed multiple myeloma (ALCYONE): final analysis of an open-label, randomised, multicentre, phase 3 trial.PMID 40220771 · 2025-May | eligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | needs_review未获得 PubMed/PMC 可审查 Figure,无法核实 KM 曲线与 No. at risk 表。 | 未获得 PubMed/PMC 可审查 Figure,无法核实 KM 曲线与 No. at risk 表。 |
| Clinical validation of droplet digital PCR assays in detecting BRAFV600-mutant circulating tumour DNA as a prognostic biomarker in patients with resected stage III melanoma receiving adjuvant therapy (COMBI-AD): a biomarker analysis from a double-blind, randomised phase 3 trial.PMID 40250457 · 2025-May | eligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | needs_review未获得 PubMed/PMC 可审查 Figure,无法核实 KM 曲线与 No. at risk 表。 | 未获得 PubMed/PMC 可审查 Figure,无法核实 KM 曲线与 No. at risk 表。 |
| Induction versus Concurrent Chemotherapy for Advanced Nasopharyngeal Carcinoma.PMID 40261119 · 2025-May | eligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | needs_review未获得 PubMed/PMC 可审查 Figure,无法核实 KM 曲线与 No. at risk 表。 | 未获得 PubMed/PMC 可审查 Figure,无法核实 KM 曲线与 No. at risk 表。 |
| Early rituximab monotherapy versus watchful waiting for advanced stage, asymptomatic, low tumour burden follicular lymphoma: long-term results of a randomised, phase 3 trial.PMID 40306831 · 2025-May | eligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | needs_review未获得 PubMed/PMC 可审查 Figure,无法核实 KM 曲线与 No. at risk 表。 | 未获得 PubMed/PMC 可审查 Figure,无法核实 KM 曲线与 No. at risk 表。 |
| Triple Oral Metronomic Chemotherapy Versus Chemotherapy of Physician Discretion After Failure of Platinum-Based Therapy in Advanced Head and Neck Cancer: A Phase III Randomized Study (METRO-CHASE Study).PMID 40403198 · 2025-May | eligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | needs_review未获得 PubMed/PMC 可审查 Figure,无法核实 KM 曲线与 No. at risk 表。 | 未获得 PubMed/PMC 可审查 Figure,无法核实 KM 曲线与 No. at risk 表。 |
| Patient-reported outcomes with trastuzumab deruxtecan in hormone receptor-positive, HER2-low or HER2-ultralow metastatic breast cancer: results from the randomized DESTINY-Breast06 trial.PMID 40441802 · 2025-May | needs_reviewThe abstract reports a randomized phase III trial with a drug intervention, but the primary/key secondary efficacy endpoint is patient-reported outcomes (quality of life), not a time-to-event endpoint such as OS, PFS, DFS, EFS, RFS, or TTP. The report is therefore excluded as a quality-of-life analysis. | pending- | The abstract reports a randomized phase III trial with a drug intervention, but the primary/key secondary efficacy endpoint is patient-reported outcomes (quality of life), not a time-to-event endpoint such as OS, PFS, DFS, EFS, RFS, or TTP. The report is therefore excluded as a quality-of-life analysis. |
| Neoadjuvant Nivolumab Plus Ipilimumab Versus Chemotherapy in Resectable Lung Cancer.PMID 39778121 · 2025-Apr-20 | eligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | needs_review历史记录已识别 KM 曲线,但旧版 Figure 审查未记录 No. at risk 表;需复核正文或补充材料。 | 历史记录已识别 KM 曲线,但旧版 Figure 审查未记录 No. at risk 表;需复核正文或补充材料。 |
| First-Line Sugemalimab Plus Chemotherapy for Advanced Gastric Cancer: The GEMSTONE-303 Randomized Clinical Trial.PMID 39992668 · 2025-Apr-15 | eligible命中用户提供的消化道肿瘤阳性参考集。 | needs_review历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。 | 历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。 |
| Cladribine Added to Idarubicin and Cytarabine as an Induction Regimen for Patients with De Novo Acute Myeloid Leukemia: A Multicenter, Randomized Phase III Trial.PMID 40008901 · 2025-Apr-14 | eligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | needs_review未获得 PubMed/PMC 可审查 Figure,无法核实 KM 曲线与 No. at risk 表。 | 未获得 PubMed/PMC 可审查 Figure,无法核实 KM 曲线与 No. at risk 表。 |
| Metronomic Capecitabine Plus Aromatase Inhibitor as Initial Therapy in Patients With Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer: The Phase III MECCA Trial.PMID 39746176 · 2025-Apr-10 | eligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | needs_review历史记录已识别 KM 曲线,但旧版 Figure 审查未记录 No. at risk 表;需复核正文或补充材料。 | 历史记录已识别 KM 曲线,但旧版 Figure 审查未记录 No. at risk 表;需复核正文或补充材料。 |